Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Group (CAN) has signed a five year supply agreement with Pure Cann New Zealand
  • Under this agreement, Cann will be the main production and manufacture partner for Pure Cann
  • Pure Cann is focusing on creating a business to supply medicinal cannabis to patients in New Zealand
  • This follows New Zealand’s new laws around medicinal cannabis that came into place earlier this month.
  • These new rules are to make it easier for doctors to prescribe medicinal cannabis and for manufacturing and cultivating licenses to be granted
  • Cann is up slightly on the market today, selling shares for 87.5¢ per share

Cann Group (CAN) has signed a five year supply agreement with Pure Cann New Zealand.

Under this agreement, Cann will be the primary production and manufacture partner for Pure Cann.

Pure Cann is building a patient-centric medicinal cannabis business and is focused on supplying medicinal cannabis to patients in New Zealand.

The country’s medicinal cannabis new rules came into effect on April 1 2020 and were put in place to make it easier for doctors to prescribe medicinal cannabis and for manufacturing and cultivating licenses to be granted.

Cann will supply products manufactured from cannabis flowers grown at Cann Group’s existing facilities, including the Mildura facility.

Cann, through its subsidiary Botanitech, holds a 3.9 per cent interest in Pure Cann. The company purchased the holding for NZ$1 million. This new agreement will also allow Cann to increase its holding to 7.7 per cent.

To receive this holding the company will purchase a further NZ$1 million in Pure Cann’s shares.

“Our ability to secure supply agreements with quality long-term partners helps support the value of our expansion plans and reinforces Cann Group as a leader in cannabis genetics, cultivation and manufacture,” Cann Group CEO Peter Crock, said.

The existing technical service agreement (TSA) between the companies has also been extended until April 2026.

Cann is up slightly on the market today, selling shares for 87.5¢ per share at market close.

CAN by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…